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Associations between selected immune-mediated
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Sreeram V Ramagopalan1,2, Raph Goldacre3, Andrew Skingsley4, Chris Conlon5 and Michael J Goldacre3*
Abstract
Background: Previous studies have suggested that there may be an association between some immune-mediated
diseases and risk of tuberculosis (TB).
Methods: We analyzed a database of linked statistical records of hospital admissions and death certificates for the
whole of England (1999 to 2011), and a similar database (the Oxford Record Linkage Study (ORLS)) for a region of
southern England in an earlier period. Rate ratios for TB were determined, comparing immune-mediated disease
cohorts with comparison cohorts.
Results: In the all-England dataset, there were significantly elevated risks of TB after hospital admission for the
following individual immune-mediated diseases: Addison's disease, ankylosing spondylitis, autoimmune hemolytic
anemia, chronic active hepatitis, coeliac disease, Crohn's disease, dermatomyositis, Goodpasture's syndrome,
Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura (ITP), myasthenia gravis, myxedema, pemphigoid,
pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis,
scleroderma, Sjögren's syndrome, systemic lupus erythematosus (SLE), thyrotoxicosis and ulcerative colitis.
Particularly high levels of risk were found for Addison’s disease (rate ratio (RR) = 11.9 (95% CI 9.5 to 14.7)),
Goodpasture’s syndrome (RR = 10.8 (95% CI 4.0 to 23.5)), SLE (RR = 9.4 (95% CI 7.9 to 11.1)), polymyositis (RR = 8.0
(95% CI 4.9 to 12.2)), polyarteritis nodosa (RR = 6.7 (95% CI 3.2 to 12.4)), dermatomyositis (RR = 6.6 (95% CI 3.0 to
12.5)), scleroderma (RR = 6.1 (95% CI 4.4 to 8.2)) and autoimmune hemolytic anemia (RR = 5.1 (95% CI 3.4 to 7.4)).
Conclusions: These two databases show that patients with some immune-mediated diseases have an increased
risk of TB, although we cannot explicitly state the direction of risk or exclude confounding. Further study of these
associations is warranted, and these findings may aid TB screening, control and treatment policies.
Keywords: Hospital episode statistics, Immune disease, Tuberculosis
Background
About one-third of the world’s population is infected with
Mycobacterium tuberculosis, but active tuberculosis (TB)
occurs in only 5% to 10% of exposed individuals [1]. The
disease may occur in any part of the body, but most com-
monly it is a pulmonary infection [1]. Manifestations of
infection range from only a mild infiltration to disease that
can be severely destructive, the balance between host
defense and bacteria determining the outcome [1].
Links between other diseases and TB have also been un-
covered. The risk of people infected with HIV developing
TB is more than 20 times greater than that of people not
infected with HIV [1]. Diabetes is associated with about a
threefold increase in tuberculosis risk [2] and alcoholism
is also associated with increased TB susceptibility [1].
In 1855, Thomas Addison described autopsy findings of
six patients with adrenal tuberculosis, which continues to
be one of the most common causes of adrenal insufficiency
in the developing world [3]. Further studies have
highlighted that immune-mediated diseases such as coeliac
disease [4] and rheumatoid arthritis [5] are associated with
an increased TB risk and there is also a suggestion that TB
may precipitate systemic lupus erythematosus (SLE) [6].
The association between TB and immune-mediated
disease has largely been ascribed to immunosuppressive
drugs such as corticosteroids and/or tumor necrosis factor
(TNF) antagonists, however this may be oversimplified.
* Correspondence: michael.goldacre@dph.ox.ac.uk
3Unit of Health-Care Epidemiology, Department of Public Health, University
of Oxford, Old Road, Oxford, OX3 7LF, UK
Full list of author information is available at the end of the article
© 2013 Ramagopalan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Ramagopalan et al. BMC Medicine 2013, 11:97
http://www.biomedcentral.com/1741-7015/11/97
Table 1 highlights further references of studies linking
TB with immune-mediated diseases; many are single
case reports and thus a relationship between TB and
these diseases cannot be established.
To investigate the association between TB and immune-
mediated disease further, we undertook record linkage
studies to determine the risk of TB specifically in individ-
uals with selected immune-mediated diseases using an
English national linked Hospital Episode Statistics (HES)
dataset and a similar regional dataset.
Methods
Population and data
For our principal analyses, we used a dataset of English
national HES (1999 to 2011), covering the population of
England of about 50 million people, combined with
statistical records of mortality. The HES data are statis-
tical records of hospital care that are compiled for every
episode of day case care or hospital admission in all
National Health Service (NHS) hospitals in England.
The death data derive from death certificates. The dataset
used in this study, in which successive records for each
individual were linked together (version 13yr-V06), was
constructed by the Oxford record linkage group.
The basic methods were the same for the analysis of
each disease and are described for rheumatoid arthritis
followed by TB. A cohort of people with a record of day
case care or inpatient admission for rheumatoid arthritis
was constructed for those with a diagnosis of rheuma-
toid arthritis in any diagnostic position on the record for
hospital care, by identifying the first episode of day case
care, or admission, for rheumatoid arthritis during
the study period. The International Classification of
Diseases, tenth edition (ICD-10) codes used for each
immune-mediated disease are shown in Table 1. The ICD
codes used for TB were A15 to A19 and B90 in the tenth
revision and equivalent codes in earlier editions. A refer-
ence cohort was constructed by identifying the first admis-
sion for each individual with various other, mainly minor
medical and surgical conditions (listed in the footnotes to
the tables), as in previous studies of disease associations
undertaken by the Oxford group [24,25]. In its design, the
standard epidemiological practice was followed, when hos-
pital controls are used, of selecting a diverse range of con-
ditions rather than relying on a narrow range (in case the
latter are themselves atypical in their risk of TB). As a
check, we have studied the risk of TB in the control condi-
tions within the reference cohort to ensure that the refer-
ence cohort did not include control conditions that have
atypically high or low TB rates.
People were included in the rheumatoid arthritis or
reference cohort if they did not have an admission for
TB either before or at the same time as the admission
for rheumatoid arthritis or the reference condition. We
then searched the database for any subsequent NHS
hospital care for, or death from, TB in these cohorts. We
included cases of TB regardless of whether TB was
recorded as the main or secondary diagnosis on the hos-
pital record, except where stated otherwise. We consid-
ered that rates of TB in the reference cohort would
approximate those in the general population of the
region while allowing for migration in and out of it (data
on migration of individuals were not available).
Statistical methods
We calculated rates of TB based on person-years. We
took ‘date of entry’ into each cohort as the date of first
admission for rheumatoid arthritis, or reference condi-
tion, and ‘date of exit’ as the date of first record of TB,
death, or the end of data collection (28 February 2011),
Table 1 England (1999–2011): number of people in the
study with each immune-mediated disease, and
percentage who were female
Immune-mediated diseases (ICD-10 codes) and
reference
N Female
(%)
Addison’s disease (E27.1) [3] 12,506 60.0
Ankylosing spondylitis (M45) [7] 30,281 30.4
Autoimmune hemolytic anemia (D59.1) [8] 9,696 54.0
Chronic active hepatitis (K73.2) 4,761 70.0
Crohn’s disease (K50) [9] 137,432 55.9
Coeliac disease (K90.0) [4] 70,300 66.5
Dermatomyositis (M33.0 to M33.1) [10] 2,903 67.1
Polymyositis (M33.2) [10] 4,130 62.3
Goodpasture’s syndrome (M31.0) [11] 1,157 49.5
Hashimoto’s thyroiditis (E06.3) 8,571 90.6
Idiopathic thrombocytopenia purpura (D69.3) [12] 31,821 54.7
Multiple sclerosis (G35) [13] 87,930 69.1
Myasthenia gravis (G70.0) [14] 11,745 49.8
Myxedema (E03.8 to E03.9) [15] 941,746 80.6
Pemphigus (L10) 2,341 57.2
Pemphigoid (L12) [16] 13,585 56.1
Pernicious anemia (D51.0) 68,679 68.4
Polyarteritis nodosa (M30.0) [17] 2,419 44.4
Primary biliary cirrhosis (K74.3) [18] 11,617 84.6
Psoriasis (L40) [19] 121,003 48.3
Rheumatoid arthritis (M05 to M06) [5] 346,804 71.1
Scleroderma (M34) [20] 12,681 81.9
Sjögren’s syndrome (M35.0) 18,791 88.6
Systemic lupus erythematosus (M32.1 to M32.9) [6] 27,519 86.7
Thyrotoxicosis (E05) 133,971 78.6
Ulcerative colitis (K51) [21] 191,977 48.7
References indicate some previous studies linking disorder with tuberculosis
(TB). ICD-10 = International Classification of Diseases, tenth edition.
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whichever was the earliest. We first calculated rates for
TB, stratified and then standardized by age (in 5-year
age groups), sex, calendar year of first recorded admis-
sion, region of residence, and quintile of patients’ Index
of Deprivation score. Since the 1970s the UK govern-
ment has calculated local measures of deprivation in
England [26]. Seven domains of deprivation are com-
bined to produce the overall index of deprivation:
income deprivation, employment deprivation, health
deprivation and disability, education skills and training
deprivation, barriers to housing and services, living
environment deprivation, and crime [26]. Each domain
represents a specific form of deprivation experienced by
people and each can be measured individually using a
number of indicators [26].
We used the indirect method of standardization, using
the combined rheumatoid arthritis and reference cohorts
as the standard population. The stratum-specific rates in
the combined rheumatoid arthritis and reference cohorts
were then applied to the number of people in each
stratum in the rheumatoid arthritis cohort, separately,
and then to those in the reference cohort, to give an
observed (O) and expected (E) number of people with
TB in each of the two cohorts. The ratio of the standard-
ized rate of occurrence of TB in the rheumatoid arthritis
cohort was calculated relative to that in the reference
cohort using the formula (ORA/ERA)/(Oref/Eref ). The
confidence interval for the rate ratio of TB and χ2 statis-
tics for its significance were calculated as described else-
where [27].
Risk of immune-mediated disease after TB
We also reversed all these procedures to study the risk
of rheumatoid arthritis (and each of the other immune-
mediated diseases) after TB. TB was taken as the expos-
ure cohort, rheumatoid arthritis as the outcome, and
rates of rheumatoid arthritis were calculated in the TB
exposure cohort and compared with those in the refer-
ence cohort, as described above. In this analysis, we ex-
cluded people from the TB or reference cohort if they
had rheumatoid arthritis before their first admission for
TB or the reference condition. This, together with simi-
lar exclusions described in the section above on rheuma-
toid arthritis as the exposure, ensured that no individual
was included in the analysis of both TB as the exposure
and as the outcome (that is, no one was counted twice).
The original Oxford Record Linkage Study (ORLS)
This is a similar dataset, unique in England in its time,
which commenced in 1963. We used the dataset from
1963 to 1998 and the same methods, originally devel-
oped to study disease associations in the ORLS [2] to in-
vestigate TB risks in people with immune-mediated
diseases in the ORLS.
Sensitivity analyses
We looked at the effects on the outcomes of each condi-
tion, separately, in the reference cohort. Where a refer-
ence condition appeared to be associated with the
outcome, we removed this condition from the reference
cohort to see if this made a difference to the results. In the
great majority of the analyses, doing this made no material
difference; in the two instances where it did make a differ-
ence, albeit small, we specify in Additional file 1.
Ethical approval
The construction and analysis of the datasets were
undertaken with the approval of the Central and South
Bristol Research Ethics Committee (REC, reference 04/
Q2006/175).
Results
Table 1 shows the number of people in the study who
were admitted to hospital with each of the selected
immune-mediated diseases; it also shows the percentage
of these who were female. The number of people in the
reference cohort was 9,026,361 (48.0% female).
Immune-mediated diseases followed by TB
There were significantly elevated risks of TB after
hospital admission for the following individual immune-
mediated diseases: Addison's disease, ankylosing spon-
dylitis, autoimmune hemolytic anemia, chronic active
hepatitis, coeliac disease, Crohn's disease, dermatomyo-
sitis, Goodpasture's syndrome, Hashimoto's thyroiditis,
idiopathic thrombocytopenia purpura, myasthenia gravis,
myxedema, pemphigoid, pernicious anemia, polyarteritis
nodosa, polymyositis, primary biliary cirrhosis, psoriasis,
rheumatoid arthritis, scleroderma, Sjögren's syndrome,
SLE, thyrotoxicosis and ulcerative colitis (Table 2).
Particularly high levels of risk were found for
Addison’s disease (rate ratio (RR) = 11.9 (95% CI, 9.5 to
14.7)), Goodpasture’s syndrome (RR = 10.8 (95% CI 4.0
to 23.5)), SLE (RR = 9.4 (95% CI 7.9 to 11.1)), polymyositis
(RR = 8.0 (95% CI 4.9 to 12.2)), polyarteritis nodosa
(RR = 6.7 (95% CI 3.2 to 12.4)), dermatomyositis (RR = 6.6
(95% CI 3.0 to 12.5)), scleroderma (RR = 6.1 (95% CI 4.4 to
8.2)) and autoimmune hemolytic anemia (RR = 5.1
(95% CI 3.4 to 7.4)).
We studied the occurrence of a first admission for TB
at least 1 year and at least 5 years after the first admis-
sion for each immune-related disease to help establish
whether any elevated risk of TB was confined to the
short term or was more prolonged, although this
reduced the statistical power within each time period
(Table 2). This analysis was largely consistent with the
all-period analysis, except that there was no significant
association of dermatomyositis, Goodpasture’s syndrome,
Hashimoto’s thyroiditis, and pemphigoid with TB risk first
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recorded at least a year after admission; and there was no
significant association of myasthenia gravis, pernicious
anemia, polymyositis, primary biliary cirrhosis and thyro-
toxicosis with TB risk first recorded least 5 years after
admission.
We also investigated the risk of respiratory and non-
respiratory TB separately (Table 3). As expected, the risk of
non-respiratory TB as compared to respiratory TB was
much greater for patients with Addison’s disease. In general,
confidence intervals for the risk of respiratory and non-
respiratory TB overlapped indicating no significant differ-
ences between the types of TB. However, non-overlapping
intervals indicated a higher risk of non-respiratory than
respiratory TB for chronic active hepatitis, Crohn’s disease,
primary biliary cirrhosis and systemic lupus erythematosus;
and a higher risk of respiratory than non-respiratory TB in
people with coeliac disease or polyarteritis nodosa.
When stratifying data by sex, there were no significant
differences between males and females.
When restricting analyses to those where an admission
for TB was recorded as the main diagnostic reason for
admission after admission for an immune-mediated dis-
ease, there were significantly elevated risks for: Addison's
disease, ankylosing spondylitis, autoimmune hemolytic
Table 2 England (1999 to 2011): rate ratios of tuberculosis following selected immune-mediated diseases (IMD)
Immune-mediated disease
(O and E for subsequent TB)
All time intervals:
rate ratio (95% CI), P value
At least 1 year after admission:
rate ratio (95% CI), P value
At least 5 years after admission:
rate ratio (95% CI), P value
Addison’s disease (85, 7.2) 11.9 (9.5 to 14.7), <0.001 11.9 (8.4 to 16.3), <0.001 11.4 (6.9 to 17.6), <0.001
Ankylosing spondylitis (75, 18) 4.2 (3.3 to 5.3), <0.001 4.1 (2.8 to 5.8), <0.001 3.9 (2.2 to 6.2), <0.001
Autoimmune hemolytic anemia (28, 5.5) 5.1 (3.4 to 7.4), <0.001 4.9 (2.5 to 8.5), <0.001 4.0 (1.1 to 10.3), 0.013
Chronic active hepatitis (13, 2.9) 4.5 (2.4 to 7.7), <0.001 5.6 (2.3 to 11.6), <0.001 5.8 (1.9 to 13.6), <0.001
Crohn’s disease (269, 76.1) 3.7 (3.2 to 4.1), <0.001 2.8 (2.3 to 3.5), <0.001 2.1 (1.5 to 2.8), <0.001
Coeliac disease (79, 34.1) 2.3 (1.9 to 2.9), <0.001 2.4 (1.6 to 3.3), <0.001 2.3 (1.4 to 3.7), <0.001
Dermatomyositis (9, 1.4) 6.6 (3.0 to 12.5), <0.001 1.8 (0.1 to 9.9), 0.9 0.0 (0.0 to 10.3), 0.8
Polymyositis (21, 2.7) 8.0 (4.9 to 12.2), <0.001 6.4 (2.8 to 12.7), <0.001 1.6 (0.0 to 8.8), 0.9
Goodpasture’s syndrome (6, 0.6) 10.8 (4.0 to 23.5), <0.001 3.9 (0.1 to 21.7), 0.6 8.4 (0.2 to 47.0), 0.3
Hashimoto’s thyroiditis (9, 4) 2.2 (1.0 to 4.3), 0.03 1.1 (0.1 to 4.0), 0.8 2.1 (0.3 to 7.4), 0.6
ITP (61, 17.7) 3.5 (2.7 to 4.5), <0.001 2.4 (1.4 to 3.7), <0.001 2.4 (1.1 to 4.6), 0.02
Multiple sclerosis (40, 48.7) 0.8 (0.6 to 1.1), 0.2 0.7 (0.4 to 1.2), 0.2 0.7 (0.3 to 1.3), 0.4
Myasthenia gravis (24, 9.1) 2.6 (1.7 to 3.9), <0.001 2.1 (1.0 to 4.0), 0.04 0.5 (0.01 to 2.6), 0.6
Myxedema (843, 566.6) 1.6 (1.5 to 1.7), <0.001 1.5 (1.4 to 1.7), <0.001 1.2 (1.0 to 1.5), 0.04
Pemphigus (2, 1.4) 1.4 (0.2 to 5.0), 0.96 1.5 (0.0 to 8.3), 0.8 0.0 (0.0 to 11.8), 0.7
Pemphigoid (17, 8.4) 2.0 (1.2 to 3.3), <0.001 1.8 (0.7 to 3.8), 0.2 1.5 (0.2 to 5.4), 0.9
Pernicious anemia (77, 40.8) 1.9 (1.5 to 2.4), <0.001 2.1 (1.5 to 2.8), <0.001 1.2 (0.6 to 2.3), 0.7
Polyarteritis nodosa (10, 1.5) 6.7 (3.2 to 12.4), <0.001 4.5 (0.9 to 13.1), 0.03 11.4 (3.1 to 29.4), <0.001
Primary biliary cirrhosis (24, 5.8) 4.1 (2.6 to 6.1), <0.001 4.2 (2.1 to 7.6), <0.001 3.1 (0.9 to 8.1), 0.05
Psoriasis (177, 69.8) 2.6 (2.2 to 3.0), <0.001 2.4 (1.9 to 3.0), <0.001 3.1 (2.2 to 4.1), <0.001
Rheumatoid arthritis (730, 249) 3.2 (3.0 to 3.5), <0.001 3.0 (2.7 to 3.4), <0.001 3.0 (2.5 to 3.5), <0.001
Scleroderma (42, 6.9) 6.1 (4.4 to 8.2), <0.001 5.3 (3.0 to 8.6), <0.001 5.0 (2.9 to 11.0), <0.001
Sjögren’s syndrome (46, 10.4) 4.4 (3.2 to 5.9), <0.001 5.1 (3.2 to 7.6), <0.001 4.0 (1.8 to 7.6), <0.001
SLE (138, 15.1) 9.4 (7.9 to 11.1), <0.001 9.1 (7.0 to 11.7), <0.001 9.1 (6.3 to 12.9), <0.001
Thyrotoxicosis (150, 74.8) 2.0 (1.7 to 2.4), <0.001 2.2 (1.7 to 2.7), <0.001 1.4 (0.8 to 2.1), 0.2
Ulcerative colitis (204, 125.2) 1.7 (1.4 to 1.9), <0.001 1.5 (1.2 to 1.8), 0.001 1.5 (1.1 to 2.0), 0.003
Table shows observed and expected (O and E) numbers of cases at all time intervals, and rate ratios and 95% confidence intervals (CIs) based on comparison with
the control cohort for (a) all time intervals, (b) cases of tuberculosis (TB) first admitted at least a year after admission for IMD, and (c) cases of TB first admitted at
least 5 years after admission for IMD. Rate ratios were adjusted for sex, age in 5-year bands, time period in single calendar years, region of residence and
deprivation score associated with patients’ area of residence, in quintiles. Conditions used in reference cohort, with Office of Population, Censuses and Surveys
(OPCS) code, fourth edition, for operations and International Classification of Diseases, tenth edition (ICD-10) code for diagnosis (with equivalent codes used for
other coding editions) were: appendectomy (OPCS4 H01 to H03), adenoidectomy (E20), tonsillectomy (F34+F36), dilation and curettage (Q10.3+Q11.4), total hip
replacement (W37 to W39), total knee replacement (W40 to W42), squint (ICD-10 H49 to H51), cataract (H25), otitis externa/media (H60 to H67), varicose veins
(I83), hemorrhoids (I84), deflected septum, nasal polyp (J33+J34.2), impacted tooth and other disorders of teeth (K00 to K03), inguinal hernia (K40), ingrowing nail,
toenail and other diseases of nail (L60), sebaceous cyst (L72.1), bunion (M20.1), internal derangement of knee (M23), dislocations, sprains and strains (S03, S13,
S23, S33, S43, S53, S63, S73, S83, S93), selected limb fractures (S42, S52, S62, S82, S92), superficial injury and contusion (S00, S10, S20, S30, S40, S50, S60, S70, S80,
S90), contraceptive management (Z30).
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anemia, chronic active hepatitis, coeliac disease, Crohn's
disease, Goodpasture's syndrome, Hashimoto's thyroiditis,
idiopathic thrombocytopenia purpura, polyarteritis nodosa,
polymyositis, psoriasis, rheumatoid arthritis, scleroderma,
SLE and ulcerative colitis (Additional file 1: Table S1).
TB followed by immune-mediated diseases
In the TB cohort there were 53,253 individuals (43.9%
female) and 9,021,678 individuals in the reference cohort
(48.0% female). There were significantly elevated risks in
people with TB for the following immune-mediated
diseases: Addison’s disease, autoimmune hemolytic anemia,
chronic active hepatitis, Crohn’s disease, Goodpasture's syn-
drome, idiopathic thrombocytopenia purpura, polyarteritis
nodosa, polymyositis, Sjögren's syndrome, SLE and thyro-
toxicosis (Table 4). When looking at risk 5 years or more
after first admission for TB, significantly increased risks
were present for Addison’s disease, Sjögren’s syndrome and
SLE (Table 4).
When stratifying the data by sex, there were significant
differences between males and females for myxedema
and rheumatoid arthritis. Females with TB had rate
ratios of 0.63 (0.57 to 0.7, P <0.001) for myxedema and
0.81 (0.68 to 0.95, P = 0.01) for rheumatoid arthritis. For
males the rate ratios were 1.04 (0.9 to 1.18, P = 0.62)
and 1.25 (1.03 to 1.51, P = 0.02) for myxedema and
rheumatoid arthritis, respectively.
When restricting analyses to just those with an admis-
sion with a main diagnosis of TB, there were signifi-
cantly elevated risks for: Addison's disease, chronic
active hepatitis, idiopathic thrombocytopenia purpura,
pernicious anemia, polyarteritis nodosa, polymyositis,
rheumatoid arthritis, SLE and ulcerative colitis (Additional
file 1: Table S2).
Corroboration from the ORLS
In the ORLS, the number of individuals who entered the
cohorts with immune-mediated diseases ranged from 79
with Goodpasture’s syndrome to 14,681 with rheumatoid
arthritis. The number of individuals who entered the TB
cohort was 7,143. There were significantly elevated risks
of TB after hospital admission for the following individual
immune-mediated diseases: Addison’s disease, ankylosing
spondylitis, chronic active hepatitis, Crohn’s disease, per-
nicious anemia, rheumatoid arthritis and systemic lupus
erythematosus (Table 5). The risk of TB was significantly
elevated in people who had their first admission for TB
at least 5 years after admission for Addison’s disease
(RR = 33.2 (95% CI 14.2 to 66.2)), chronic active hepa-
titis (RR = 25.2 (95% CI 3.0 to 91.8)), Crohn’s disease
(RR = 5.5 (95% CI 2.2 to 11.4)), rheumatoid arthritis (RR =
2.6 (95% CI 1.6 to 4.1)) and SLE (RR = 25.2 (95% CI 3.0 to
91.8)). The risk for Addison’s disease, dermatomyositis,
Goodpasture’s syndrome, SLE, myxedema and chronic
active hepatitis after admission for TB was significantly
elevated. For example, the risk of first admission for
Addison’s disease was significantly elevated 5 years after
first admission for TB (RR = 6.7 (95% CI 2.6 to 14.5)).
Discussion
Previous reports [4,5,10,21], combined with the results
we present here, suggest that there is an association be-
tween some immune-mediated diseases and the risk of
subsequent TB. Rates of subsequent TB were signifi-
cantly high in both the all-England and the ORLS
datasets for Addison’s disease, ankylosing spondylitis,
chronic active hepatitis, Crohn’s disease, pernicious anemia,
rheumatoid arthritis, and systemic lupus erythematosus. In
addition, in the England dataset alone there were sig-
nificantly high risks of TB following admission for
Table 3 England (1999 to 2011): rate ratios for
respiratory and non-respiratory tuberculosis (TB) for
people with immune-mediated diseases
Immune-mediated disease Respiratory TB
rate ratio,
(95% CI)
Non-respiratory
TB rate ratio,
(95% CI)
Addison's disease 6.5 (4.4 to 9.4) 33.0 (25.1 to 42.6)
Ankylosing spondylitis 4.6 (3.4 to 6.0) 4.7 (2.8 to 7.3)
Autoimmune hemolytic anemia 7.2 (4.6 to 10.7) 4.3 (1.4 to 10.1)
Chronic active hepatitis 3.0 (1.0 to 7.0) 9.3 (3.7 to 19.3)
Crohn's disease 3.3 (2.8 to 3.9) 5.7 (4.6 to 6.9)
Coeliac disease 2.8 (2.2 to 3.7) 1.6 (0.9 to 2.7)
Dermatomyositis 9.6 (4.2 to 19.0) 5.3 (0.6 to 19.2)
Polymyositis 8.7 (4.8 to 14.7) 8.7 (3.2 to 18.9)
Goodpasture's syndrome 11.3 (3.1 to 29.0) 15.0 (1.8 to 54.4)
Hashimoto's thyroiditis 2.9 (1.2 to 6.0) 1.8 (0.2 to 6.5)
Idiopathic thrombocytopenia
purpura
3.8 (2.7 to 5.1) 5.3 (3.4 to 8.0)
Multiple sclerosis 1.0 (0.6 to 1.4) 0.8 (0.4 to 1.5)
Myasthenia gravis 3.1 (1.9 to 5.0) 2.5 (0.8 to 5.9)
Myxedema 1.6 (1.5 to 1.8) 2.0 (1.7 to 2.2)
Pemphigus 1.1 (0.0 to 6.2) 6.2 (0.8 to 22.3)
Pemphigoid 2.3 (1.2 to 4.1) 3.1 (1.0 to 7.3)
Pernicious anemia 2.2 (1.6 to 2.8) 2.4 (1.4 to 3.7)
Polyarteritis nodosa 8.6 (3.7 to 16.9) 3.0 (0.1 to 16.9)
Primary biliary cirrhosis 4.0 (2.1 to 6.8) 7.9 (4.1 to 13.8)
Psoriasis 2.9 (2.4 to 3.5) 2.5 (1.8 to 3.4)
Rheumatoid arthritis 3.6 (3.2 to 3.9) 3.2 (2.7 to 3.8)
Scleroderma 6.2 (4.0 to 9.1) 3.8 (1.5 to 7.8)
Sjögren's syndrome 4.8 (3.2 to 6.9) 4.8 (2.5 to 8.2)
Systemic lupus erythematosus 8.4 (6.6 to 10.5) 14.6 (11.3 to 18.7)
Thyrotoxicosis 2.3 (1.9 to 2.8) 2.4 (1.7 to 3.2)
Ulcerative colitis 1.7 (1.4 to 2.0) 1.8 (1.4 to 2.4)
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autoimmune hemolytic anemia, coeliac disease, derm-
atomyositis, Goodpasture's syndrome, Hashimoto's thy-
roiditis, idiopathic thrombocytopenia purpura, myasthenia
gravis, myxedema, pemphigoid, polyarteritis nodosa, poly-
myositis, primary biliary cirrhosis, psoriasis, scleroderma,
Sjögren's syndrome, thyrotoxicosis and ulcerative colitis.
A lack of significance in the ORLS dataset does not neces-
sarily imply that the English data are uncorroborated find-
ings; the ORLS dataset may merely be underpowered to
detect these effects. Though small numbers of patients
with the immune-mediated diseases, and with TB, may
appear both in the ORLS and later in the Oxford element
of HES, the ORLS and the much larger and later English
national dataset are largely independent of each other.
There was also evidence of an increased risk for some
immune-mediated diseases after TB, but the question of
which disorder came first is difficult to disentangle.
Information to determine the direction of the associ-
ation between these diseases and TB would need inci-
dence dates of development of each disease; and these
are not available. We looked at the risks for TB first
recorded after a year and after 5 years of first admission
for each immune-mediated disease (and vice versa) in
order to minimize the risk of detection bias or any
misdiagnosis between immune-mediated diseases and
subsequent recognition that they were, instead, manifes-
tations of TB. We also did this to help interpretation of
the causal direction of the associations. Of interest in
Table 4 England (1999 to 2011): rate ratios of immune-mediated disease (IMD) following tuberculosis (TB)
Immune-mediated disease (O and E) All time intervals:
rate ratio (95% CI), P value
At least 1 year after admission:
rate ratio (95% CI), P value
At least 5 years after admission:
rate ratio (95% CI), P value
Addison’s disease (74, 9.6) 8.0 (6.3 to 10.1), <0.001 10.6 (7.4 to 14.8), <0.001 4.7 (2.2 to 8.7), <0.001
Ankylosing spondylitis (30, 32.9) 0.9 (0.6 to 1.3), 0.7 1.1 (0.5 to 1.9), 0.9 0.9 (0.3 to 1.9), 0.8
Autoimmune hemolytic anemia (16, 6.3) 2.6 (1.5 to 4.2), <0.001 2.2 (0.8 to 4.9), 0.1 0.7 (0.0 to 3.6), 1
Chronic active hepatitis (14, 2.9) 4.9 (2.6 to 8.2), <0.001 2.7 (0.7 to 7.1), 0.1 3.7 (0.4 to 13.6), 0.2
Crohn’s disease (101, 75.9)a 1.3 (1.1 to 1.6), 0.005 1.0 (0.8 to 1.3), 1.0 0.7 (0.4 to 1.2), 0.3
Coeliac disease (45, 45.0) 1.00 (0.7 to 1.3), 0.9 1.0 (0.6 to 1.5), 1.0 0.7 (0.3 to 1.4), 0.4
Dermatomyositis (3, 1.6) 1.9 (0.4 to 5.5), 0.5 4.4 (0.9 to 13.1), 0.03 0.0 (0.0 to 9.4), 0.9
Polymyositis (10, 3.3) 3.1 (1.5 to 5.7), 0.001 2.3 (0.5 to 6.7), 0.3 2.5 (0.3 to 9.0), 0.5
Goodpasture’s syndrome (4, 0.8) 5.1 (1.4 to 13.1), 0.003 0.0 (0.0 to 10.4), 0.8 0.0 (0.0 to 17.3), 0.5
Hashimoto’s thyroiditis (7, 6.1) 1.2 (0.5 to 2.4), 0.9 1.3 (0.3 to 3.8), 0.9 0.0 (0.0 to 2.2), 0.4
ITP (49, 22.4) 2.2 (1.6 to 2.9), <0.001 2.2 (1.3 to 3.4), 0.001 1.7 (0.8 to 3.1), 0.2
Multiple sclerosis (17, 49.2) 0.3 (0.2 to 0.6), <0.001 0.7 (0.3 to 1.2), 0.2 0.5 (0.2 to 1.2), 0.2
Myasthenia gravis (10, 10.1) 1.0 (0.5 to 1.8), 0.9 1.5 (0.6 to 3.3), 0.4 0.9 (0.1 to 3.3), 0.9
Myxedema (649, 888.8) 0.7 (0.7 to 0.8), <0.001 1.1 (1.0 to 1.2), 0.1 0.9 (0.8 to 1.0), 0.2
Pemphigus (4, 2.3) 1.8 (0.5 to 4.5), 0.4 0.9 (0.2 to 2.3), 1 0.0 (0.0 to 6.1), 0.9
Pemphigoid (12, 10.9) 1.1 (0.6 to 1.9), 0.9 1.2 (0.0 to 6.7), 0.7 2.1 (0.8 to 4.4), 0.1
Pernicious anemia (74, 63.2) 1.2 (0.9 to 1.5), 0.2 1.3 (0.9 to 1.9), 0.2 1.3 (0.8 to 2.0), 0.2
Polyarteritis nodosa (8, 1.8) 4.5 (1.9 to 9.0), <0.001 8.2 (3.0 to 18.2), <0.001 2.1 (0.1 to 11.8), 1.0
Primary biliary cirrhosis (13, 8.0) 1.6 (0.9 to 2.8), 0.1 1.8 (0.7 to 4.0), 0.2 1.0 (0.1 to 3.5), 0.8
Psoriasis (108, 119.9) 0.9 (0.7 to 1.1), 0.3 1.4 (1.0 to 1.8), 0.04 0.9 (0.5 to 1.3), 0.5
Rheumatoid arthritis (259, 271.8)b 0.9 (0.8 to 1.1), 0.5 1.1 (1.0 to 1.3), 0.1 1.0 (0.7 to 1.2), 0.8
Scleroderma (14, 8.8) 1.6 (0.9 to 2.7), 0.1 1.1 (0.3 to 2.9), 1 1.6 (0.4 to 4.2), 0.5
Sjögren’s syndrome (35, 17.8) 2.0 (1.4 to 2.8), <0.001 2.1 (1.2 to 3.6), <0.001 2.6 (1.4 to 4.6), <0.001
SLE (82, 23.2) 3.6 (2.9 to 4.5), <0.001 4.4 (3.1 to 6.0), <0.001 2.5 (1.3 to 4.3). <0.001
Thyrotoxicosis (141, 117.1) 1.2 (1.0 to 1.4), 0.03 1.5 (1.2 to 1.9), <0.001 1.1 (0.8 to 1.6), 0.5
Ulcerative colitis (106, 121.8) 0.9 (0.7 to 1.1), 0.2 0.9 (0.7 to 1.2), 0.5 0.9 (0.6 to 1.3), 0.6
The table shows observed numbers of cases of selected immune-mediated diseases in people with TB; showing observed and expected (O and E) numbers of
cases at all time intervals, and rate ratios and 95% CIs based on comparison with the control cohort for (a) all time intervals , (b) cases of IMD first admitted at
least a year after admission for TB, and (c) cases of IMD first admitted at least 5 years after admission for TB. aFor Crohn’s disease, the reference cohort was
adjusted to remove appendectomy and hemorrhoids as these conditions were found to have elevated risks for Crohn’s disease. We present these ‘adjusted’
results in the Table. The unadjusted results for all time intervals were as follows: 101 observed, 90.8 expected, RR 1.1 (95% CI 0.9 to 1.4, P = 0.3). bFor rheumatoid
arthritis, the reference cohort was adjusted to remove hip replacement and knee replacement as these operations are associated with rheumatoid arthritis in
some patients. We present these ‘adjusted’ results in the Table. The unadjusted results for all time intervals were as follows: 259 observed, 337.2 expected, RR 0.8
(95% CI 0.7 to 0.9, P = 0.3).
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this respect are Addison’s, Sjögren’s and SLE showing
associations in both directions in the 5-year analysis. It
is likely that the great majority of cases of Addison’s are
caused by TB. There is also evidence to suggest that TB
may be an infective trigger for immune-mediated dis-
ease, mechanistically by molecular mimicry, bystander
activation or acting as an adjuvant [22,23].
The associations between other immune-mediated dis-
eases, and their mechanisms, warrant further attention.
One possible mechanism could be immune dysfunction
predisposing to both immune-mediated disease and TB.
Whether this dysfunction leads to an increased suscepti-
bility to infection with TB or a greater risk of TB activa-
tion will be important to tease out. Another possible
mechanism is the effect of treatment of autoimmune
diseases on TB risk. Immunosuppressive drugs such as
corticosteroids have long been associated with the risk
of TB, and more recently, TNF antagonists have also
been shown to increase risk [1]. In addition, patients
who are on these therapies are more likely to be inten-
sively investigated for infections, including TB, if compli-
cations arise during treatment. These are perhaps the
most likely explanation for some of the associations ob-
served. However, even when excluding individuals treated
with TNF antagonists, studies have observed an increased
risk for TB in patients with rheumatoid arthritis [5]. Vita-
min D deficiency as a result of immune-mediated disease
increasing TB risk has also been hypothesized [28].
Based on our data, screening for latent TB at immune-
mediated disease diagnosis and regular timely screening
thereafter may be beneficial. This will be especially true
where we have identified particularly high levels of risk
and/or where pre-existing data corroborate our findings.
Although we have grouped these disorders together as
immune mediated, these diseases are looked after by a di-
verse range of specialists (hematologists, rheumatologists,
dermatologists, endocrinologists, hepatologists, respira-
tory physicians). Raising awareness of the importance of
screening for TB in this context is more difficult but needs
to be put in place.
A key strength of the dataset is its size with large
numbers of fairly uncommon diseases. The risk of TB
was studied within a single population, using the same
methodology, which means that direct comparisons of
risk between immune-mediated diseases can be made.
The dataset has limitations. The data is based on preva-
lent cases of immune-mediated diseases and of TB (the
first recorded hospital admission or episode of day case
care for each person with each condition) rather than
being a cohort with follow-up from the date of first diag-
nosis. Data are not recorded on patients who move out
of the area covered by data collection or who are treated
in hospitals outside the area. The dataset is limited to
people who were admitted to hospital, or who received
day case specialist care and thus there exists the poten-
tial for selection bias. This would not capture all people
with each immune-mediated disease, although it should
identify the great majority with subsequent diagnosed
TB. We lack treatment data for immune-mediated dis-
eases. There is very limited information on potential
confounding factors such as detailed socioeconomic
characteristics, other co-infections (for example, HIV
Table 5 Oxford Record Linkage Study (ORLS) (1963 to 1998)a: rate ratios for tuberculosis (TB) in people with
immune-mediated disease (IMD) and for immune-mediated disease in people with tuberculosis
Exposure (earlier admission) Outcome (later admission) Observed Expected Rate ratio (95% CI) P value
Addison's disease† Tuberculosis 15 0.8 20.06 (11.18 to 33.27) <0.001
Ankylosing spondylitis Tuberculosis 6 1.6 3.87 (1.42 to 8.46) 0.002
Chronic active hepatitis‡ Tuberculosis 4 0.3 12.32 (3.35 to 31.66) <0.001
Crohn's disease Tuberculosis 18 4 4.61 (2.72 to 7.33) <0.001
Pernicious anemia Tuberculosis 25 11.1 2.28 (1.47 to 3.39) <0.001
Rheumatoid arthritis Tuberculosis 69 26.7 2.71 (2.09 to 3.46) <0.001
SLEb Tuberculosis 8 0.5 17.29 (7.44 to 34.22) <0.001
Tuberculosis Addison's diseaseb 13 1.9 7.6 (3.94 to 13.48) <0.001
Tuberculosis Chronic active hepatitisc 6 1.2 5.37 (1.93 to 12.07) <0.001
Tuberculosis Goodpasture's syndromeb 2 0.3 8.09 (0.91 to 34.08) 0.018
Tuberculosis Myxedemab 36 23.1 1.57 (1.1 to 2.18) 0.009
Tuberculosis SLEb 7 1.4 5.31 (2.1 to 11.21) <0.001
Tuberculosis Dermatomyositisb 3 0.4 8.18 (1.6 to 26.15) 0.001
The table shows observed numbers of cases of TB in people with selected immune-mediated diseases, and observed numbers of cases of selected immune-
mediated diseases in people with TB; expected number of cases, rate ratios and 95% confidence intervals (CIs) based on comparison with the control cohort for
statistically significant comparisons. aYears 1963 to 1998 unless otherwise stated (span of years depends on whether the disease is separately identifiable in earlier
editions of the International Classification of Diseases (ICD)). bCases identified from 1968 to 1998 (that is, from ICD-8 onwards). cCases identified from 1979 to 1998
(that is, from ICD-9 onwards.
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with idiopathic thrombocytopenia purpura), ethnicity
and smoking. The majority of individuals in the ORLS
were born in Britain, and thus associations seen in the
ORLS are in a reasonably homogeneous population in
respect of ethnicity. The effect of making multiple
comparisons needs to be considered. For this reason, we
have given exact P values, as well as confidence intervals,
so that the reader can judge the degree of significance for
each immune-mediated disease and subsequent TB. It is
possible that some of the associations that are significant
at a level of P <0.05 may result from making multiple
comparisons and the play of chance. This may particularly
be so where there is no prior hypothesis to support the
finding. However, many of the associations are very
strong, and levels of significance high, and it is unlikely
that most of these are attributable to chance alone. The
ORLS data is also helpful in this regard: associations be-
tween several diseases and increased risks of TB were seen
consistently in this smaller dataset suggesting that, taking
the findings from both datasets together, these are not
chance findings. The fact that we see the classic associ-
ation between Addison’s and TB, and confirm previous
findings of association between coeliac disease and
rheumatoid arthritis and TB [4,5] adds further weight to
the validity of our datasets and analyses.
Conclusions
Our results should be regarded as speculative rather than
definitive. They need further work, in different study de-
signs, to confirm or refute the findings. Further studies
should employ prospective longitudinal cohorts of individ-
uals with TB and, separately, cohorts of individuals with
immune-mediated disease to truly understand the mech-
anism behind the associations described. In countries
where TB is uncommon the relative risks present translate
into a small absolute risk increase. Nevertheless, these
data may help to increase awareness among clinicians of a
possible increased risk of TB in patients with autoimmune
diseases. This could, in turn, lead to better screening, and
treatment, for latent TB in this patient population.
Additional file
Additional file 1: Table S1. Shows data analysis results for the rate
ratios of primary diagnosis of tuberculosis following selected immune-
mediated diseases (IMD) in England, 1999 to 2011. Table S2. Shows the
data analysis results for the rate ratios of immune-mediated disease
following a principal diagnosis of tuberculosis in England, 1999 to 2011.
Abbreviations
E: Expected; HES: Hospital episode statistics; ITP: Idiopathic
thrombocytopenia purpura; ICD: International classification of disease;
NHS: National health service; O: Observed; ORLS: Oxford record linkage study;
RR: Rate ratio; TB: Tuberculosis; TNF: Tumor necrosis factor; SLE: Systemic
lupus erythematosus.
Competing interests
The authors declare no competing interests.
Authors’ contributions
MJG is the guarantor and designer of the study. RG led the analysis. SVR, AS
and MJG contributed to the analysis and interpretation of the data. SVR
wrote the first draft and all authors contributed to subsequent drafts and the
final paper. All authors have read and approve the manuscript for
publication.
Acknowledgements
The Unit of Health-Care Epidemiology and its work on record linkage are
funded by the English National Institute for Health Research. The study
sponsors had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; or preparation, review,
or approval of the manuscript. All authors state that this research was carried
out independently of the influence of funding bodies.
Author details
1Department of Physiology, Anatomy and Genetics and Medical Research
Council Functional Genomics Unit, University of Oxford, Parks Road, Oxford,
OX1 3PT, UK. 2Blizard Institute, Queen Mary University of London, Barts and
the London School of Medicine and Dentistry, 4 Newark Street, London, E1
2AT, UK. 3Unit of Health-Care Epidemiology, Department of Public Health,
University of Oxford, Old Road, Oxford, OX3 7LF, UK. 4Imperial College
Medical School, Exhibition Road, London, SW7 2AZ, UK. 5Department of
Infectious Diseases and Microbiology, Oxford University NHS Trust, John
Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.
Received: 28 September 2012 Accepted: 4 February 2013
Published: 4 April 2013
References
1. Lawn SD, Zumla AI: Tuberculosis. Lancet 2011, 378:57–72.
2. Young F, Wotton CJ, Critchley JA, Unwin NC, Goldacre MJ: Increased risk of
tuberculosis disease in people with diabetes mellitus: record-linkage
study in a UK population. J Epidemiol Community Health 2012, 66:519–523.
3. Patnaik MM, Deshpande AK: Diagnosis-Addison’s disease secondary to
tuberculosis of the adrenal glands. Clin Med Res 2008, 6:29.
4. Ludvigsson JF, Wahlstrom J, Grunewald J, Ekbom A, Montgomery SM:
Coeliac disease and risk of tuberculosis: a population based cohort
study. Thorax 2007, 62:23–28.
5. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P,
Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T,
Romanus V, Klareskog L, Feltelius N: Risk and case characteristics of
tuberculosis in rheumatoid arthritis associated with tumor necrosis
factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986–1992.
6. Lin Y-C, Liang S-J, Liu Y-H, Hsu W-H, Shih C-M, Sung F-C, Chen W:
Tuberculosis as a risk factor for systemic lupus erythematosus: results of
a nationwide study in Taiwan. Rheumatol Int 2012, 32:1669–1673.
7. Kim E-M, Uhm W-S, Bae S-C, Yoo D-H, Kim T-H: Incidence of tuberculosis
among korean patients with ankylosing spondylitis who are taking
tumor necrosis factor blockers. J Rheumatol 2011, 38:2218–2223.
8. Bakhshi S, Rao IS, Jain V, Arya LS: Autoimmune hemolytic anemia
complicating disseminated childhood tuberculosis. Indian J Pediatr 2004,
71:549–551.
9. Deetlefs E, Epstein D, Watermeyer GA, Seggie RM, Thomson SR:
Tuberculosis in an inflammatory bowel disease cohort from South Africa.
S Afr Med J 2012, 102:802–804.
10. Airio A, Kauppi M, Kautiainen H, Hakala M, Kinnula V: High association of
mycobacterial infections with polymyositis in a non-endemic country for
tuberculosis. Ann Rheum Dis 2007, 66:1404–1405.
11. Wen Y-K, Wen K-I: Pulmonary hemorrhage complicating Goodpasture’s
disease in the course of pulmonary tuberculosis. Int Urol Nephrol 2012.
12. Tabarsi P, Merza MA, Marjani M: Active pulmonary tuberculosis
manifesting with idiopathic thrombocytopenic purpura: a rare
presentation. Braz J Infect Dis 2010, 14:639–640.
13. Andersen E, Isager H, Hyllested K: Risk factors in multiple sclerosis:
tuberculin reactivity, age at measles infection, tonsillectomy and
appendectomy. Acta Neurol Scand 1981, 63:131–135.
Ramagopalan et al. BMC Medicine 2013, 11:97 Page 8 of 9
http://www.biomedcentral.com/1741-7015/11/97
14. Ou S-M, Liu C-J, Chang Y-S, Hu Y-W, Chao P-W, Chen T-J, Tzeng C-H, Wang S-J:
Tuberculosis in myasthenia gravis. Int J Tuberc Lung Dis 2013,
17:79–84.
15. Barnes P, Weatherstone R: Tuberculosis of the thyroid: two case reports.
Br J Dis Chest 1979, 73:187–191.
16. Goodfellow A, Keeling DN, Hayes RC, Webster D: Utility of an
interferon-gamma release assay for latent tuberculosis diagnosis in a
case of bullous pemphigoid. J Cutan Med Surg 2009, 13:280–282.
17. Imanishi H, Tsuruta D, Oshimo T, Sowa J, Mizuno N, Nakagawa K, Ishii M:
Cutaneous polyarteritis nodosa induced by Mycobacterium tuberculosis.
J Dermatol 2012, 39:738–739.
18. Vogel Y, Bous JC, Winnekendonk G, Henning BF: Tuberculous peritonitis in
a German patient with primary biliary cirrhosis: a case report. J Med Case
Rep 2008, 2:32.
19. Bordignon V, Bultrini S, Prignano G, Sperduti I, Piperno G, Bonifati C,
Filippetti M, Toma L, Latini A, Di Cecio M, Giuliani A, Vocaturo A, Trento E,
D’Agosto G, Francesconi F, Cataldo A, Vento A, Cilenti V, Berardesca E,
Ameglio F, Cordiali Fei P, Ensoli F: High prevalence of latent tuberculosis
infection in autoimmune disorders such as psoriasis and in chronic
respiratory diseases, including lung cancer. J Biol Regul Homeost Agents
2011, 25:213–220.
20. Roddy J, Holtby S, Seigel S: Scleroderma concurrent with culture proven
tuberculosis in a Japanese Canadian patient. J Rheumatol 1996,
23:2168–2170.
21. Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD: Risk for
active tuberculosis in inflammatory bowel disease patients.
Clin Gastroenterol Hepatol 2007, 5:1070–1075.
22. Asherson RA, Gunter K, Daya D, Shoenfeld Y: Multiple autoimmune
diseases in a young woman: tuberculosis and splenectomy as possible
triggering factors? Another example of the “mosaic” of autoimmunity.
J Rheumatol 2008, 35:1224–1226.
23. Ribeiro FM, Szyper-Kravitz M, Klumb EM, Lannes G, Ribeiro FRE, Albuquerque
EMM, Shoenfeld Y: Can lupus flares be associated with tuberculosis
infection? Clin Rev Allergy Immunol 2010, 38:163–168.
24. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ: Cancer in patients
with motor neuron disease, multiple sclerosis and Parkinson’s disease:
record linkage studies. J Neurol Neurosurg Psychiatry 2010, 81:215–221.
25. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ: Risk of
venous thromboembolism in people admitted to hospital with selected
immune-mediated diseases: record-linkage study. BMC Med 2011, 9:1.
26. UK Office of National Statistics: UK indices of multiple deprivation - a way to
make comparisons across constituent countries easier. http://www.ons.gov.uk/
ons/rel/hsq/health-statistics-quarterly/no–53–spring-2012/uk-indices-of-
multiple-deprivation.html.
27. Breslow NE, Day NE: Statistical methods in cancer research. The design and
analysis of cohort studies. IARC Sci Publ 1987, 2(82):1–406.
28. Shapira Y, Agmon-Levin N, Shoenfeld Y: Mycobacterium tuberculosis,
autoimmunity, and vitamin D. Clin Rev Allergy Immunol 2010, 38:169–177.
doi:10.1186/1741-7015-11-97
Cite this article as: Ramagopalan et al.: Associations between selected
immune-mediated diseases and tuberculosis: record-linkage studies.
BMC Medicine 2013 11:97.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ramagopalan et al. BMC Medicine 2013, 11:97 Page 9 of 9
http://www.biomedcentral.com/1741-7015/11/97
